JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Janus kinase (JAK) inhibition may be a promising new treatment modality for inflammatory (skin) diseases. However, little is known about direct effects of kinase inhibitors on keratinocyte differentiation and function as well as skin barrier formation. Objective: Our aim was to address the direct impact of kinase inhibition of the JAK1/3 pathways by tofacitinib on keratinocyte immune function and barrier formation in atopic dermatitis (AD) and psoriasis. Methods: 3D skin equivalents of both diseases were developed and concurrently pretreated with tofacitinib. To induce AD, 3D skin equivalents were stimulated with recombinant human IL‐4 and IL‐13. Psoriasis‐like conditions were induced by incubation with IL‐17A, IL‐22 and tumour necrosis factor α (TNFα). The activation of signal transducer and activator of transcription (STAT)1, STAT3 and STAT6 was assessed by Western blot analysis. Microarray analysis and quantitative real‐time PCR were used for gene expression analysis. Results: Tofacitinib pretreatment preserved epidermal morphology and reduced STAT3 and STAT6 phosphorylation of AD‐like and STAT3 phosphorylation of psoriasis‐like culture conditions in 3D skin models compared to sham‐controls. Filaggrin expression was fully maintained in the AD‐like models, but only partially in psoriasis‐like conditions after pretreatment with tofacitinib. In addition, tofacitinib upregulated DSC1, FLG and KRT1. Using gene expression analysis, downregulation of POSTN and IL24 was observed in AD‐like conditions, whereas downregulation of IL20 and IL1B was observed in psoriasis‐like conditions. Conclusion: JAK1/3 inhibition counteracted cytokine‐induced AD‐ and psoriasis‐like epidermal morphology and enhanced keratinocyte differentiation in 3D skin models. This effect was more pronounced in the AD‐like models compared to the psoriasis‐like 3D skin models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Cited by
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments
Quílez, C., Bebiano, L. B., Jones, E., Maver, U., Meesters, L., Parzymies, P., Petiot, E., Rikken, G., Risueño, I., Zaidi, H., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.04.032 · Cited by 65
In Vitro and Ex Vivo Models for Screening Topical Anti-Inflammatory Drugs
Pérez-Salas, J. L., Moreno-Jiménez, M. R., Rocha-Guzmán, N. E., González-Laredo, R. F., Medina-Torres, L., & Gallegos-Infante, J. A. (2023) · Scientia Pharmaceutica · doi:10.3390/scipharm91020020 · Cited by 22
“[77] developed 3D skin equivalents for atopic dermatitis and psoriasis.”
BackgroundBioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
Stanton, D. N., Ganguli-Indra, G., Indra, A. K., & Karande, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020319 · Cited by 22
Scheurer, J., Sauer, B., Focken, J., Giampetraglia, M., Jäger, A., Schürch, C. M., Weigelin, B., & Schittek, B. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050541 · Cited by 21
“…inhibits intracellular JAK/signal transducers and activators of transcription (STAT) signaling pathways, both of which play a role in pro-inflammatory effects of many cytokines that are also present in AD and psoriasis (Clarysse et al., 2019; O ’ Shea and Murray, 2008; O ’ Shea et al., 2015).”
Metadata
- Authors
- Clarysse, K., Pfaff, C. M., Marquardt, Y., Huth, L., Kortekaas Krohn, I., Kluwig, D., Lüscher, B., Gutermuth, J., & Baron, J.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2019-01
- Volume
- 33
- Issue
- 2
- Pages
- 367-375
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W2898471473
- Cited by
- 64
- References
- 4
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis. https://app.cochat.ai/papers/10.1111/jdv.15301
- The paper
- Clarysse, K., Pfaff, C. M., Marquardt, Y., Huth, L., Kortekaas Krohn, I., Kluwig, D., Lüscher, B., Gutermuth, J., & Baron, J. (2019). JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.15301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.